Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 6.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,656 shares of the biotechnology company’s stock after selling 10,756 shares during the period. Ascendis Pharma A/S accounts for about 1.2% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 19th biggest holding. Rice Hall James & Associates LLC owned about 0.26% of Ascendis Pharma A/S worth $20,683,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Private Ocean LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter valued at about $36,000. Quadrant Capital Group LLC grew its holdings in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares in the last quarter. GAMMA Investing LLC increased its position in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 102 shares during the period. Finally, Barometer Capital Management Inc. bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $126,000.

Ascendis Pharma A/S Trading Down 1.8 %

Shares of Ascendis Pharma A/S stock opened at $114.76 on Wednesday. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The company has a market cap of $6.68 billion, a P/E ratio of -11.94 and a beta of 0.63. The stock has a 50-day moving average price of $133.61 and a 200 day moving average price of $137.33.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ASND shares. TD Cowen decreased their price target on Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. Jefferies Financial Group increased their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Evercore ISI upgraded shares of Ascendis Pharma A/S to a “strong-buy” rating in a research report on Monday, August 26th. Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an “equal weight” rating in a report on Thursday, May 16th. Finally, Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Moderate Buy” and a consensus target price of $187.08.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.